HC Wainwright Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock Price

Repligen (NASDAQ:RGEN) had its price objective lowered by HC Wainwright from $240.00 to $180.00 in a research note released on Thursday morning, Marketbeat reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

RGEN has been the subject of a number of other reports. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Finally, Wolfe Research started coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $184.73.

Repligen Price Performance

RGEN opened at $165.89 on Thursday. The business’s 50-day moving average is $150.83 and its two-hundred day moving average is $146.23. The firm has a market capitalization of $9.29 billion, a PE ratio of -448.34, a price-to-earnings-growth ratio of 4.51 and a beta of 0.97. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the company posted $0.23 earnings per share. Research analysts anticipate that Repligen will post 1.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently bought and sold shares of the company. First Turn Management LLC acquired a new position in Repligen during the 3rd quarter worth approximately $13,202,000. Thrivent Financial for Lutherans raised its stake in shares of Repligen by 6.1% during the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after purchasing an additional 36,773 shares during the last quarter. Geneva Capital Management LLC increased its stake in shares of Repligen by 8.5% during the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock worth $20,638,000 after acquiring an additional 10,908 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Repligen during the 2nd quarter worth $5,320,000. Finally, TimesSquare Capital Management LLC boosted its stake in shares of Repligen by 14.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock worth $41,019,000 after acquiring an additional 35,115 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.